Kymab Limited, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on the development of innovative therapies for autoimmune diseases and cancer. Founded in 2010, Kymab has made significant strides in the biotechnology sector, particularly with its proprietary antibody platform, which enables the creation of unique monoclonal antibodies. The company’s flagship product, KY1005, is designed to modulate immune responses, showcasing Kymab's commitment to addressing unmet medical needs. With a strong presence in both the UK and the US, Kymab has established itself as a key player in the biopharmaceutical industry, recognised for its cutting-edge research and development capabilities. Notable achievements include successful clinical trials and strategic partnerships that enhance its market position and drive future growth.
We don't have data for Kymab Limited, but we can show you information about their parent organization instead.
View parent company